Personalized Radiopharmaceutical Compositions with Enhanced Stability and Targeting

The present inventive concept relates to next-generation radiopharmaceutical compositions and methods that leverage advances in biodegradable polymers, personalized medicine, and real-time monitoring to enhance diagnostic accuracy and treatment efficacy.

The original patent provided a stable radiopharmaceutical composition of tetrofosmin, but it had limitations in terms of controlled release, targeting, and stability. The new inventive concept addresses these limitations by introducing biodegradable polymer matrices, customized ligands, and real-time monitoring systems to create personalized radiopharmaceutical compositions with improved stability and targeting capabilities.

The new inventive concept comprises a tetrofosmin-based radiotracer embedded in a biodegradable polymer matrix, designed to release the radiotracer in a controlled manner for improved diagnostic accuracy. Additionally, the concept involves a method for producing personalized radiopharmaceutical compositions by analyzing a patient's genetic profile to identify a specific biomarker and formulating a customized ligand that targets the identified biomarker. The concept also includes a lyophilized kit with a pH-adjusting agent to optimize the radiotracer's stability and efficacy, as well as a system for real-time monitoring of radiopharmaceutical composition stability.

The new claims introduce the use of biodegradable polymer matrices, customized ligands, and real-time monitoring systems, which are not present in the original patent. These features provide a significant improvement in controlled release, targeting, and stability, making the new inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept could include the use of different biodegradable polymers, varying the pH-adjusting agent, or incorporating additional therapeutic agents. Variations could also include adapting the concept for different disease types or patient populations.

The new inventive concept has significant commercial potential in the field of radiopharmaceuticals, particularly in the areas of personalized medicine and targeted therapies. The market for radiopharmaceuticals is expected to grow significantly in the coming years, driven by increasing demand for effective diagnostic and therapeutic tools.